The Slovenian translational platform GlioBank for brain tumor research: Identification of molecular signatures of glioblastoma progression

GlioBank is a centralized biobank that has been built by a multidisciplinary network with the aim of facilitating disease-oriented basic and clinical research. The advantages of GlioBank include the molecular characterization of GB based on targeted gene expression, the availability of diverse cellular models (eg, GB cells and organoids), and a large number of patient-matched tumor core and rim samples, all with accompanying molecular and clinical data. We report here for the first time an association between <i>DAB2</i> expression and low overall survival in GB patients, indicative of a prognostic value of <i>DAB2</i>.